Neurocrine Biosciences (NBIX) cleared a benchmark Wednesday. The Relative Strength Rating for Neurocrine jumped from 77 to 82. Some technical analysts see a Relative Strength Rating of 80 or higher as a buy signal. Investors' Business. Continue reading
Biotechnology stocks have been doing very well for the past several weeks. There are different investment. Continue reading
LivaNova PLC (LIVN) announced today that its latest VNS Therapy systems received FDA approval for expanded MRI. Continue reading
Trump Sinks Drug Stocks on Medicare Drug Price Negotiation. President Donald Trump supports Medicare drug price. Continue reading
A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other. Continue reading
Biotech stocks as a group have suffered a tough start to the year, but traders are beginning to see a turnaround. Continue reading
The pharmaceuticals sector is facing an intensive period of mergers and acquisitions in the coming years, even if. Continue reading
While following blindly in the footsteps of billionaires is risky, it's always interesting to see what stocks. Continue reading
A powerful and inexpensive technique for rewriting snippets of DNA — known as CRISPR-Cas9 — has two research. Continue reading
Biotechnology companies Celgene Corp. and Gilead Sciences Inc. are considering bids for Medivation Inc., which. Continue reading
